Immunology Unit, Dasman Diabetes Institute, Kuwait, Kuwait.
Biochemistry and Molecular Biology Unit, Dasman Diabetes Institute, Kuwait, Kuwait.
Diabetes Metab Res Rev. 2019 Feb;35(2):e3087. doi: 10.1002/dmrr.3087. Epub 2018 Nov 8.
Chemokines produced by adipose tissue (AT) are involved in the development of chronic low-grade inflammation in obese humans and rodents. AT CCL19 expression in obesity and its association with metabolic inflammation and insulin resistance are poorly understood. This study aimed to investigate the effects of CCL19 gene expression on inflammatory markers in subcutaneous AT and insulin resistance.
Subcutaneous adipose samples were collected from 56 non-diabetic (26-obese, 21-overweight, and 9-lean) individuals. Expression of CCL19 and inflammatory markers was determined using real-time RT-PCR. Plasma C-reactive protein (CRP) and adiponectin were measured by ELISA. Insulin sensitivity was assessed using homeostasis model assessment index (HOMA).
CCL19 expression was significantly higher in obese compared with lean individuals (P < 0.034). The elevated expression of CCL19 associated positively with body mass index (r = 0.253; P = 0.049). CCL19 expression correlated positively with IL-8 (r = 0.39; P = 0.006), IL-12 (r = 0.43; P = 0.003), IP-10 (r = 0.25; P = 0.07), CCL5 (r = 0.37; P = 0.011), CCR2 (r = 0.44; P = 0.001), and CCR5 (r = 0.35; P = 0.009). Additionally, CCL19 was positively correlated with triglycerides (TG: r = 0.41; P = 0.001), fasting blood glucose (FBG: r = 0.49; P < 0.0001), glycated haemoglobin (HbA1c: r = 0.396; P = 0.001), and CRP (r = 0.387; P = 0.019) whereas it had negative association with HDL cholesterol (r = -0.282; P = 0.035) and adiponectin (-0.393; P = 0.019). Notably, HOMA-IR correlated positively with CCL19 (r = 0.38; P = 0.01). In multiple regression analysis, CCL19 is an independent predictor of IL-8 and IL-12.
These data demonstrate that increased AT expression of CCL19 in obesity may represent a molecular link between metabolic inflammation and insulin resistance.
脂肪组织(AT)产生的趋化因子参与肥胖人群和啮齿动物中慢性低度炎症的发展。脂肪组织 CCL19 在肥胖症中的表达及其与代谢性炎症和胰岛素抵抗的关系尚不清楚。本研究旨在探讨 CCL19 基因表达对皮下脂肪组织中炎症标志物和胰岛素抵抗的影响。
从 56 名非糖尿病患者(26 名肥胖者、21 名超重者和 9 名瘦弱者)中采集皮下脂肪样本。使用实时 RT-PCR 测定 CCL19 和炎症标志物的表达。通过 ELISA 测定血浆 C 反应蛋白(CRP)和脂联素。使用稳态模型评估指数(HOMA)评估胰岛素敏感性。
与瘦者相比,肥胖者的 CCL19 表达显著升高(P<0.034)。CCL19 的高表达与体重指数呈正相关(r=0.253;P=0.049)。CCL19 表达与 IL-8(r=0.39;P=0.006)、IL-12(r=0.43;P=0.003)、IP-10(r=0.25;P=0.07)、CCL5(r=0.37;P=0.011)、CCR2(r=0.44;P=0.001)和 CCR5(r=0.35;P=0.009)呈正相关。此外,CCL19 与甘油三酯(TG:r=0.41;P=0.001)、空腹血糖(FBG:r=0.49;P<0.0001)、糖化血红蛋白(HbA1c:r=0.396;P=0.001)和 CRP(r=0.387;P=0.019)呈正相关,而与高密度脂蛋白胆固醇(r=-0.282;P=0.035)和脂联素(r=-0.393;P=0.019)呈负相关。值得注意的是,HOMA-IR 与 CCL19 呈正相关(r=0.38;P=0.01)。多元回归分析显示,CCL19 是 IL-8 和 IL-12 的独立预测因子。
这些数据表明,肥胖症中脂肪组织 CCL19 的表达增加可能是代谢性炎症和胰岛素抵抗之间的分子联系。